
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc is experiencing a positive shift in its financial projections, with its FY26 EPS estimates being raised significantly from $(8.63) to $(4.17) due to an increase in share count, indicating improved expectations for the company's performance. The anticipated FDA approval of the MyoVista device and its accompanying algorithm is expected to significantly enhance the market presence of both the MyoVista device and the MyoVista Insights cloud software platform, positioning the company for substantial growth. With a new price target of $9.20 reflecting a threefold potential increase, HeartSciences is poised to capitalize on a large market opportunity in the cardiac diagnostic sector.
Bears say
HeartSciences Inc. faces a significant downward revision of its FY2026 revenue estimate, decreasing from $1.2 million to $0.1 million due to FDA-related delays, which underscores substantial challenges in bringing products to market. The company’s operating expenses remain relatively controlled, coming in at $1.9 million against estimates of $2.0 million; however, this is overshadowed by the myriad risks it faces, including balance sheet and liquidity risks, along with potential failure in clinical trials and regulatory approvals. Overall, the combination of these revenue forecasts and associated risks raises serious concerns about HeartSciences's ability to effectively commercialize its AI-powered ECG diagnostic solutions in a competitive healthcare landscape.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares